Sharon Cunningham, co-founder & CEO of Shorla Pharma Ltd. (dba Shorla Oncology), gave a CEO’s perspective on navigating the extended downturn facing public biotechs. She stressed the importance of having a “cash conservation mindset” in which the company needs to forecast its runway further into the future than was previously necessary, and potentially identify areas where pipeline priorities need to shift.
Read more at: https://www.biocentury.com/article/643677
